INDEX TO VOLUME 8

Author Index

A

Ader R: *See* **Giang DW**
Akil M: *See* **Musser WS**
Albert MS: *See* **Savage CR**
Albert P: *See* **Morris PLP** (spring)
Alim TN: *See* **Rosse RB**
Allen D: *See* **Scott TF**
Andreasen NC: *See* **Nopoulos P**
Andreasen NC, O'Leary DS, Arndt S, Cizadlo T, Hurtig R, Rezai K, Watkins L, Boles Ponto L, Hichwa RD: Neural substrates of facial recognition. Spring 139–146
Apter S: *See* **Trestman RL**
Arndt S: *See* **Andreasen NC**
Aronowitz BR: *See* **Cohen LJ**
Arruda JE: *See* **Stern RA**

B

Baer L: *See* **Savage CR**
Basser P *See* **George MS** (spring)
Bennett EL, Diamond MC, Krech D, Rosenzweig MR: Chemical and anatomical plasticity of brain (classic article; introduction by Neylan TC). Fall 458–470
Benson DF: Neuropsychiatry and behavioral neurology: past, present, and future (neuropsychiatric practice and opinion). Summer 351–357
Berthier ML, Kulisevsky J, Gironell A, Fernández-Benitez JA: Poststroke bipolar affective disorder: clinical subtypes, concurrent movement disorders, and anatomical correlates. Spring 160–167
Boles Ponto L: *See* **Andreasen NC**
Boutros NN, Bowers MB Jr: Chronic substance-induced psychotic disorders: state of the literature. Summer 262–269
Bowers MB Jr: Plasma HVA and MHPG in psychiatric patients with renal failure and levodopa-treated Parkinson's disease (clinical and research report). Fall 450–452; *see also* **Boutros NN**
Brandt J: *See* **Rasmusson DX**
Brillman J: *See* **McConnell H**
Brower CA: *See* **Kurlan R**
Brown HD: *See* **Savage CR**
Buccino DL: *See* **Hackerman F**
Buchsbaum MS: *See* **Siegel BV Jr; Hoffman RE**
Burt DR: *See* **Creese I**
Byun HS: *See* **Lyoo IK**

C

Cahn DA, Malloy PF, Salloway S, Rogg J, Gillard E, Kohn R, Tung G, Richardson ED, Westlake R: Subcortical hyperintensities on MRI and activities of daily living in geriatric depression. Fall 404–411
Campbell M: *See* **Kafantaris V**
Casanova MF, Kruesi M, Mannheim G: Multiple sclerosis and bipolar disorder: a case report with autopsy findings (clinical and research report). Spring 206–208
Cassar J, Vieweg WVR: Auditory hallucinations and agenesis of the left internal carotid artery (letter). Spring 231
Cavalier J: *See* **McConnell H**
Chapman MM: *See* **Filley CM**
Charney DS: *See* **Karper LP**
Chatham-Showalter PE: Carbamazepine for combativeness in acute traumatic brain injury (clinical and research report). Winter 96–99
Chemerinski E: *See* **Petracca G**
Cizadlo T: *See* **Andreasen NC**
Coccaro E: *See* **Trestman RL; Stein DJ**
Cohen LJ, Hollander E, DeCaria CM, Stein DJ, Simeon D, Liebowitz MR, Aronowitz BR: Specificity of neuropsychological impairment in obsessive-compulsive disorder: a comparison with social phobic and normal control subjects (clinical and research report). Winter 82–84
Cohen N: *See* **Giang DW**
Cole SA, Woodard JL, Juncos JL, Kogos JL, Youngstrom EA, Watts RL: Depression and disability in Parkinson's disease. Winter 20–25
Commissaris K, Verhey FRJ, Jolles J: A controlled study into the effects of psychoeducation for patients with cognitive disturbances. Fall 429–435
Como PG: *See* **Kurlan R**
Condray R: *See* **Morrow LA**
Corazzini K: *See* **Lyketsos CG**
Creese I, Burt DR, Snyder SH: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs (classic article; introduction by Neylan TC). Spring 222–226
Cress K: *See* **McConnell H**
Cummings JL: Neuropsychiatry and society (neuropsychiatric practice and opinion). Winter 104–109
Cutler NR, Veroff AE, Frackiewicz EJ, Welke TL, Kurtz NM, Sramek JJ: Assessing the neuropsychological profile of stable schizophrenic outpatients. Fall 423–428

D

Dal Forno G: *See* **Rasmusson DX**
Dancygier G: *See* **Pozzi D**
Daragjati C: *See* **Kurlan R**
Davidson M: *See* **Trestman RL**
DeCaria CM: *See* **Cohen LJ**
de Carvalho ML: *See* **Morris PLP** (spring)
Defilippi JL: *See* **Wagner ML**
DeQuardo JR: *See* **Lewis CF**
Deutsch SI: *See* **Rosse RB**
Diamond MC: *See* **Bennett EL**
Doss R: *See* **Mendez MF**
Dubovsky SL: *See* **Filley CM**
Duffy JD: *See* **McConnell H**
Duffy JD, Kant R: Clinical utility of clozapine in 16 patients with neurological disease (clinical and research report). Winter 92–96

E

Eden-Fetzer D: *See* **Morris PLP** (spring)
Eichelman BS: *Neurobiology of Violence*, by Volavka J (book review). Summer 358
Elliott FS: *See* **Linnville SE**
El-Mallakh RS, Pant B, Looney SW: Nerve conduction velocity and H-reflex recovery in bipolar illness. Fall 412–416
Engebrit B: *See* **Mendez MF**
Evans JD, Paulsen JS, Harris MJ, Heaton RK, Jeste DV: A clinical and neuropsychological comparison of delusional disorder and schizophrenia. Summer 281–286

F

Fawcett J: *See* **Sabelli H**
Fernández-Benitez JA: *See* **Berthier ML**
Filley CM, Chapman MM, Dubovsky SL: Ethical concerns in the use of palliative drug treatment for Alzheimer's disease (clinical and research report). Spring 202–205; Reply to Walsh (letter). Summer 361–362
Fink M: "Abnormal" EEG effects of clozapine (letter). Winter 114–115 (Risby

INDEX TO VOLUME 8

Author Index

A

Ader R: *See* **Giang DW**
Akil M: *See* **Musser WS**
Albert MS: *See* **Savage CR**
Albert P: *See* **Morris PLP** (spring)
Alim TN: *See* **Rosse RB**
Allen D: *See* **Scott TF**
Andreasen NC: *See* **Nopoulos P**
Andreasen NC, O'Leary DS, Arndt S, Cizadlo T, Hurtig R, Rezai K, Watkins L, Boles Ponto L, Hichwa RD: Neural substrates of facial recognition. Spring 139–146
Apter S: *See* **Trestman RL**
Arndt S: *See* **Andreasen NC**
Aronowitz BR: *See* **Cohen LJ**
Arruda JE: *See* **Stern RA**

B

Baer L: *See* **Savage CR**
Basser P *See* **George MS** (spring)
Bennett EL, Diamond MC, Krech D, Rosenzweig MR: Chemical and anatomical plasticity of brain (classic article; introduction by Neylan TC). Fall 458–470
Benson DF: Neuropsychiatry and behavioral neurology: past, present, and future (neuropsychiatric practice and opinion). Summer 351–357
Berthier ML, Kulisevsky J, Gironell A, Fernández-Benitez JA: Poststroke bipolar affective disorder: clinical subtypes, concurrent movement disorders, and anatomical correlates. Spring 160–167
Boles Ponto L: *See* **Andreasen NC**
Boutros NN, Bowers MB Jr: Chronic substance-induced psychotic disorders: state of the literature. Summer 262–269
Bowers MB Jr: Plasma HVA and MHPG in psychiatric patients with renal failure and levodopa-treated Parkinson's disease (clinical and research report). Fall 450–452; *see also* **Boutros NN**
Brandt J: *See* **Rasmusson DX**
Brillman J: *See* **McConnell H**
Brower CA: *See* **Kurlan R**
Brown HD: *See* **Savage CR**
Buccino DL: *See* **Hackerman F**
Buchsbaum MS: *See* **Siegel BV Jr; Hoffman RE**
Burt DR: *See* **Creese I**
Byun HS: *See* **Lyoo IK**

C

Cahn DA, Malloy PF, Salloway S, Rogg J, Gillard E, Kohn R, Tung G, Richardson ED, Westlake R: Subcortical hyperintensities on MRI and activities of daily living in geriatric depression. Fall 404–411
Campbell M: *See* **Kafantaris V**
Casanova MF, Kruesi M, Mannheim G: Multiple sclerosis and bipolar disorder: a case report with autopsy findings (clinical and research report). Spring 206–208
Cassar J, Vieweg WVR: Auditory hallucinations and agenesis of the left internal carotid artery (letter). Spring 231
Cavalier J: *See* **McConnell H**
Chapman MM: *See* **Filley CM**
Charney DS: *See* **Karper LP**
Chatham-Showalter PE: Carbamazepine for combativeness in acute traumatic brain injury (clinical and research report). Winter 96–99
Chemerinski E: *See* **Petracca G**
Cizadlo T: *See* **Andreasen NC**
Coccaro E: *See* **Trestman RL; Stein DJ**
Cohen LJ, Hollander E, DeCaria CM, Stein DJ, Simeon D, Liebowitz MR, Aronowitz BR: Specificity of neuropsychological impairment in obsessive-compulsive disorder: a comparison with social phobic and normal control subjects (clinical and research report). Winter 82–84
Cohen N: *See* **Giang DW**
Cole SA, Woodard JL, Juncos JL, Kogos JL, Youngstrom EA, Watts RL: Depression and disability in Parkinson's disease. Winter 20–25
Commissaris K, Verhey FRJ, Jolles J: A controlled study into the effects of psychoeducation for patients with cognitive disturbances. Fall 429–435
Como PG: *See* **Kurlan R**
Condray R: *See* **Morrow LA**
Corazzini K: *See* **Lyketsos CG**
Creese I, Burt DR, Snyder SH: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs (classic article; introduction by Neylan TC). Spring 222–226
Cress K: *See* **McConnell H**
Cummings JL: Neuropsychiatry and society (neuropsychiatric practice and opinion). Winter 104–109
Cutler NR, Veroff AE, Frackiewicz EJ, Welke TL, Kurtz NM, Sramek JJ: Assessing the neuropsychological profile of stable schizophrenic outpatients. Fall 423–428

D

Dal Forno G: *See* **Rasmusson DX**
Dancygier G: *See* **Pozzi D**
Daragjati C: *See* **Kurlan R**
Davidson M: *See* **Trestman RL**
DeCaria CM: *See* **Cohen LJ**
de Carvalho ML: *See* **Morris PLP** (spring)
Defilippi JL: *See* **Wagner ML**
DeQuardo JR: *See* **Lewis CF**
Deutsch SI: *See* **Rosse RB**
Diamond MC: *See* **Bennett EL**
Doss R: *See* **Mendez MF**
Dubovsky SL: *See* **Filley CM**
Duffy JD: *See* **McConnell H**
Duffy JD, Kant R: Clinical utility of clozapine in 16 patients with neurological disease (clinical and research report). Winter 92–96

E

Eden-Fetzer D: *See* **Morris PLP** (spring)
Eichelman BS: *Neurobiology of Violence*, by Volavka J (book review). Summer 358
Elliott FS: *See* **Linnville SE**
El-Mallakh RS, Pant B, Looney SW: Nerve conduction velocity and H-reflex recovery in bipolar illness. Fall 412–416
Engebrit B: *See* **Mendez MF**
Evans JD, Paulsen JS, Harris MJ, Heaton RK, Jeste DV: A clinical and neuropsychological comparison of delusional disorder and schizophrenia. Summer 281–286

F

Fawcett J: *See* **Sabelli H**
Fernández-Benitez JA: *See* **Berthier ML**
Filley CM, Chapman MM, Dubovsky SL: Ethical concerns in the use of palliative drug treatment for Alzheimer's disease (clinical and research report). Spring 202–205; Reply to Walsh (letter). Summer 361–362
Fink M: "Abnormal" EEG effects of clozapine (letter). Winter 114–115 (Risby

ED, Epstein CM: Reply. Winter 115–116)
Fink P: *See* **Sabelli H**
Fogel BS: *See* **Ott BR**
Forrest DV: *The Psychotherapist's Guide to Neuropsychiatry: Diagnostic and Treatment Issues*, edited by Ellison JM, Weinstein CS, Hodel-Malinofsky T (book review). Spring 227–228; *Pyramidal Neural Networks*, by Bischof H (book review). Fall 472–473
Frackiewicz EJ: *See* **Cutler NR**
Freeman GK: *See* **Karper LP**

G

Gallucci G: *See* **Hackerman F**
García H: *See* **Pozzi D**
George MS, Wassermann EM, Post RM: Transcranial magnetic stimulation: a neuropsychiatric tool for the 21st century. Fall 373–382
George MS, Wassermann EM, Williams WA, Steppel J, Pascual-Leone A, Basser P, Hallett M, Post RM: Changes in mood and hormone levels after rapid-rate transcranial magnetic stimulation (rTMS) of the prefrontal cortex. Spring 172–180
Giang DW, Goodman AD, Schiffer RB, Mattson DH, Petrie M, Cohen N, Ader R: Conditioning of cyclophosphamide-induced leukopenia in humans. Spring 194–201
Gillard E: *See* **Cahn DA**
Gironell A: *See* **Berthier ML**
Goodman AD: *See* **Giang DW**
Grau R: *See* **Mendez MF**
Grillon C: *See* **Karper LP**
Gross H, Kling A, Henry G, Herndon C, Lavretsky H: Local cerebral glucose metabolism in patients with long-term behavioral and cognitive deficits following mild traumatic brain injury. Summer 324–334
Guich SM: *See* **Hoffman RE**

H

Hackerman F, Buccino DL, Gallucci G, Schmidt CW Jr: The effect of a split in WAIS-R VIQ and PIQ scores on patients with cognitive impairment and psychiatric illness (clinical and research report). Winter 85–87
Haier RJ: *See* **Siegel BV Jr**
Hallett M: *See* **George MS** (spring)
Hamakawa H: *See* **Kato T**
Handelsman L: *See* **Schroeder MM**
Harris MJ: *See* **Evans JD**
Heaton RK: *See* **Evans JD**
Henry G: *See* **Gross H**
Herndon C: *See* **Gross H**
Hess AL: *See* **Rosse RB**
Hichwa RD: *See* **Andreasen NC**
Hoffman RE, Buchsbaum MS, Jensen RV, Guich SM, Tsai K, Nuechterlein KH: Dimensional complexity of EEG waveforms in neuroleptic-free schizophrenic patients and normal control subjects. Fall 436–441
Hollander E: *See* **Cohen LJ; Stein DJ**
Hooten WM, Lyketsos CG: Frontotemporal dementia: a clinicopathological review of four postmortem studies. Winter 10–19
Hopwood MJ: *See* **Morris PLP** (fall)
Horvath T: *See* **Trestman RL**
House A: Depression associated with stroke (neuropsychiatric practice and opinion). Fall 453–457
Hurtig R: *See* **Andreasen NC**

I

Inubushi T: *See* **Kato T**

J

Jacobson J: *See* **Schroeder MM**
Jenike MA: *See* **Savage CR**
Jensen RV: *See* **Hoffman RE**
Jeste DV: *See* **Evans JD**
Johri SK: *See* **Rosse RB**
Jolles J: *See* **Commissaris K**
Juncos JL: *See* **Cole SA**

K

Kafantaris V, Lee DO, Magee H, Winney G, Samuel R, Pollack S, Campbell M: Assessment of children with the Overt Aggression Scale. Spring 186–193
Kalus O: *See* **Trestman RL**
Kant R: *See* **Duffy JD**
Karper LP, Freeman GK, Grillon C, Morgan CA III, Charney DS, Krystal JH: Preliminary evidence of an association between sensorimotor gating and distractibility in psychosis. Winter 60–66
Kato T, Murashita J, Shioiri T, Hamakawa H, Inubushi T: Effect of photic stimulation on energy metabolism in the human brain measured by ^{31}P-MR spectroscopy. Fall 417–422
Kendrick AD: *See* **Savage CR**
Kendrick K: *See* **Rosse RB**
Keuthen NJ: *See* **Savage CR**
Kim SW: *See* **Zald DH** (spring, summer)
Kishi Y, Robinson RG: Suicidal plans following spinal cord injury: a six-month study (clinical and research report). Fall 442–445
Kling A: *See* **Gross H**
Kogos JL: *See* **Cole SA**
Kohn R: *See* **Cahn DA**
Kraus MF: *See* **Lyketsos CG**
Krech D: *See* **Bennett EL**
Kruesi M: *See* Casanova MF
Krystal JH: *See* **Karper LP**
Kulisevsky J: *See* **Berthier ML**
Kunik M: *Behavioral Complications in Alzheimer's Disease*, edited by Lawlor B (book review). Fall 472
Kurlan R: *See* **Richard IH**
Kurlan R, Daragjati C, Como PG, McDermott MP, Trinidad KS, Roddy S, Brower CA, Robertson MM: Nonobscene complex socially inappropriate behavior in Tourette's syndrome. Summer 311–317
Kurtz NM: *See* **Cutler NR**

L

Lalonde FM, Martin A, Myslobodsky MS: Increased prevalence of septal cavitation in a nonschizophrenic sample: an MRI study of HIV-infected individuals. Winter 47–53
Lang D: *See* **Scott TF**
Larson GE: *See* **Linnville SE**
Lavretsky H: *See* **Gross H**
Law WA: *See* **Mapou RL**
Lee DO: *See* **Kafantaris V**
Leiguarda R: *See* **Petracca G**
Lewis CF, DeQuardo JR, Tandon R: ECT in genetically confirmed Huntington's disease (clinical and research report). Spring 209–210
Liebowitz MR: *See* **Cohen LJ**
Linnville SE, Elliott FS, Larson GE: Event-related potentials as indices of subclinical neurological differences in HIV patients during rapid decision making. Spring 293–304
Lipsey JR: *See* **Ranen NG**
Looney SW: *See* **El-Mallakh RS**
Luchins D: *See* **Pankow L**
Lyketsos C: *See* **Hooten WM; Rasmusson DX**
Lyketsos CG, Corazzini K, Steele CD, Kraus MF: Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Winter 67–73
Lyoo IK, Seol HY, Byun HS, Renshaw PF: Unsuspected multiple sclerosis in patients with psychiatric disorders: a magnetic resonance imaging study. Winter 54–59

M

Magee H: *See* **Kafantaris V**
Malec JF: DSM-IV postconcussional disorder: recommendations (letter). Winter 113–114
Malloy PF: *See* **Cahn DA**
Malone JL: *See* **Mapou RL**
Mannheim G: *See* **Casanova MF**

Mapou RL, Law WA, Wagner K, Malone JL, Skillman DR: Neuropsychological effects of Interferon Alfa-n3 treatment in human immunodeficiency virus-1–infected individuals. Winter 74–81
Martin A: *See* **Lalonde FM**
Mattson DH: *See* **Giang DW**
McConnell H: *See* **Scott TF**
McConnell H, Snyder PJ, Duffy JD, Weilburg J, Valeriano J, Brillman J, Cress K, Cavalier J: Neuropsychiatric side effects related to treatment with felbamate (clinical and research report). Summer 341–346
McDermott MP: *See* **Kurlan R**
McInnes A: *Adrenergic Dysfunction and Psychobiology*, edited by Cameron OG (book review). Winter 112
Mender D: On neuropsychiatry and society (letter). Summer 362–363
Mendez MF, Engebrit B, Doss R, Grau R: The relationship of epileptic auras and psychological attributes. Summer 287–292
Menza MA: *See* **Wagner ML**
Miguel EC: *See* **Savage CR**
Mitropoulou V: *See* **Trestman RL; Stein DJ**
Morgan CA III: *See* **Karper LP**
Morris PLP, Robinson RG, de Carvalho ML, Albert P, Wells JC, Samuels JF, Eden-Fetzer D, Price TR: Lesion characteristics and depressed mood in the stroke data bank study. Spring 153–159
Morris PLP, Robinson RG, Raphael B, Hopwood MJ: Lesion location and poststroke depression. Fall 399–403
Morrow LA, Steinhauer SR, Condray R: Differential associations of P300 amplitude and latency with cognitive and psychiatric function in solvent-exposed adults (clinical and research report). Fall 446–449
Murashita J: *See* **Kato T**
Musser WS, Akil M: Clozapine as a treatment for psychosis in Parkinson's disease: a review. Winter 1–9
Myslobodsky MS: *See* **Lalonde FM**

N

Nuechterlein KH: *See* **Hoffman RE**
Neylan TC: Pathophysiology of schizophrenia: dopamine hypothesis (introduction to Creese et al). Spring 222; Brain plasticity: influence of environment (introduction to Bennett et al). Fall 458–459
Nopoulos P, Swayze V, Andreasen NC: Pattern of brain morphology in patients with schizophrenia and large cavum septi pellucidi. Spring 147–152
Noto RB: *See* **Ott BR**

O

O'Leary DS: *See* **Andreasen NC**
Opler LA: *Clinical and Neurobiological Advances in Psychiatry, Vol. 1: Advances in the Neurobiology of Schizophrenia*, edited by Den Boer JA, Westenberg HGM, van Praag HM (book review). Spring 229–230
Ott BR, Noto RB, Fogel BS: Apathy and loss of insight in Alzheimer's disease: a SPECT imaging study. Winter 41–46

P

Pankow L, Pliskin N, Luchins D: An optical intervention for visual hallucinations associated with visual impairment and dementia in elderly patients (clinical and research report). Winter 88–92
Pant B: *See* **El-Mallakh RS**
Pascual-Leone A: *See* **George MS** (spring)
Paulsen JS: *See* **Evans JD**
Peterson AE: *See* **Trestman RL**
Petracca G, Tesón A, Chemerinski E, Leiguarda R, Starkstein SE: A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. Summer 270–275
Petracchi M: *See* **Pozzi D**
Petrie M: *See* **Giang DW**
Pliskin N: *See* **Pankow L**
Podell K: Reply to Watt (letter). Spring 233–234
Pollack S: *See* **Kafantaris V**
Post RM: *See* **George MS** (spring, fall)
Pozzi D, Vázquez S, Petracchi M, Dancygier G, García H, Starkstein S: Quantified electroencephalographic correlates of relative frontal or parietal hypoperfusion in dementia. Winter 26–32
Prange AR Jr: *See* **Stern RA**
Price TR: *See* **Morris PLP** (spring)
Price TRP: *See* **Scott TF**
Prohaska ML: *See* **Stern RA**

R

Ranen NG, Lipsey JR, Treisman G, Ross CA: Sertraline in the treatment of severe aggressiveness in Huntington's disease (clinical and research report). Summer 338–340
Raphael B: *See* **Morris PLP** (fall)
Rasmusson DX, Dal Forno G, Brandt J, Warren AC, Troncoso J, Lyketsos C: Apo-E genotype and verbal deficits in Alzheimer's disease (clinical and research report). Summer 335–337
Rauch SL: *See* **Savage CR**
Renshaw PF: *See* **Lyoo IK**
Rezai K: *See* **Andreasen NC**
Richard IH, Schiffer RB, Kurlan R: Anxiety and Parkinson's disease. Fall 383–392
Richardson ED: *See* **Cahn DA**
Risby ED, Epstein CM: Reply to Fink (letter). Winter 115–116
Ritter W: *See* **Schroeder MM**
Robertson MM: *See* **Kurlan R**
Robinson B: *See* **Stern RA**
Robinson RG: *See* **Kishi Y; Morris PLP** (spring, fall)
Roddy S: *See* **Kurlan R**
Rogg J: *See* **Cahn DA**
Rosenzweig MR: *See* **Bennett EL**
Ross CA: *See* **Ranen NG**
Rosse RB, Johri SK, Hess AL, Kendrick K, Alim TN, Deutsch SI: A measure of pupillary oscillation as a marker of cocaine-induced paranoia (clinical and research report). Summer 347–350

S

Sabelli H, Fink P, Fawcett J, Tom C: Sustained antidepressant effect of PEA replacement. Spring 168–171
Sage JI: *See* **Wagner ML**
Salloway S: *Brain Activation*, by Roland P (book review). Winter 111–112; Clinical-pathological case conference: depression, behavior change, and subcortical dementia in a 57-year-old woman (neuropsychiatric practice and opinion). Spring 215–221; *see also* **Cahn DA**
Samuel R: *See* **Kafantaris V**
Samuels JF: *See* **Morris PLP** (spring)
Savage CR, Keuthen NJ, Jenike MA, Brown HD, Baer L, Kendrick AD, Miguel EC, Rauch SL, Albert MS: Recall and recognition memory in obsessive-compulsive disorder (clinical and research report). Winter 99–103
Schiffer RB: *See* **Giang DW; Richard IH**
Schleifer SJ: *Stress, the Immune System, and Psychiatry*, edited by Leonard BE, Miller K (book review). Spring 228–229
Schmidt CW Jr: *See* **Hackerman F**
Schroeder MM, Handelsman L, Torres L, Jacobson J, Ritter W: Consistency of repeated event-related potentials in clinically stable HIV-1–infected drug users. Summer 305–310
Scott TF, Allen D, Price TRP, McConnell H, Lang D: Characterization of major depression symptoms in multiple sclerosis patients. Summer 318–323
Seol HY: *See* **Lyoo IK**
Shihabuddin L: *See* **Siegel BV Jr**
Shioiri T: *See* **Kato T**

Sieg KG: Abnormal septum pellucidum morphology in Tourette's syndrome (letter). Fall 474
Siegel BV Jr, Shihabuddin L, Buchsbaum MS, Starr A, Haier RJ, Valladares Neto DC: Gender differences in cortical glucose metabolism in Alzheimer's disease (clinical and research report). Spring 211–214
Siever LJ: *See* **Trestman RL; Stein DJ**
Simeon D: *See* **Cohen LJ**
Skillman DR: *See* **Mapou RL**
Snyder PJ: *See* **McConnell H**
Snyder SH: *See* **Creese I**
Sramek JJ: *See* **Cutler NR**
Starkstein SE: *See* **Petracca G; Pozzi D**
Starr A: *See* **Siegel BV Jr**
Steele CD: *See* **Lyketsos CG**
Stein DJ: *See* **Cohen LJ**
Stein DJ, Trestman RL, Mitropoulou V, Coccaro EF, Hollander E, Siever LJ: Impulsivity and serotonergic function in compulsive personality disorder. Fall 393–398
Steinhauer SR: *See* **Morrow LA**
Steppel J: *See* **George MS** (spring)
Stern RA, Robinson B, Thorner AR, Arruda JE, Prohaska ML, Prange AR Jr: A survey study of neuropsychiatric complaints in patients with Graves' disease. Spring 181–185
Swayze V: *See* **Nopoulos P**

T

Tandon R: *See* **Lewis CF**
Tesón A: *See* **Petracca G**
Thorner AR: *See* **Stern RA**
Tom C: *See* **Sabelli H**
Torres L: *See* **Schroeder MM**
Treisman G: *See* **Ranen NG**
Trestman RL: *See* **Stein DJ**
Trestman RL, Horvath T, Kalus O, Peterson AE, Coccaro E, Mitropoulou V, Apter S, Davidson M, Siever LJ: Event-related potentials in schizotypal personality disorder. Winter 33–40
Trinidad KS: *See* **Kurlan R**
Troncoso J: *See* **Rasmusson DX**
Tsai K: *See* **Hoffman RE**
Tung G: *See* **Cahn DA**

V

Valeriano J: *See* **McConnell H**
Valladares Neto DC: *See* **Siegel BV Jr**
Vázquez S: *See* **Pozzi D**
Verhey FRJ: *See* **Commissaris K**
Veroff AE: *See* **Cutler NR**
Vieweg WVR: *See* **Cassar J**
Volavka J: *Impulsivity and Aggression*, edited by Hollander E, Stein DJ (book review). Winter 110–111
Vompe L: Cross-cultural perspective in treatment of brain injury (letter). Winter 116

W

Wagner K: *See* **Mapou RL**
Wagner ML, Defilippi JL, Menza MA, Sage JI: Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients. Summer 276–280
Walczak T: *Epilepsy and the Functional Anatomy of the Frontal Lobe*, edited by Jasper HH, Riggio S, Goldman-Rakic PS (book review). Fall 471–472
Walsh AC: Anticoagulant therapy for Alzheimer's disease (letter). Summer 361 (Filley CM, Chapman MM, Dubovsky SL: Reply. Summer 361–362)
Warren AC: *See* **Rasmusson DX**
Wassermann EM: *See* **George MS** (spring, fall)
Watkins L: *See* **Andreasen NC**
Watt DF: Projective testing and lateralization (letter). Spring 232–233 (Podell K: Reply. Spring 233–234); *Clinical Neuropsychology*, edited by Heilman KM, Valenstein E (book review). Summer 359–360
Watts RL: *See* **Cole SA**
Weilburg J: *See* **McConnell H**
Welke TL: *See* **Cutler NR**
Wells JC: *See* **Morris PLP** (spring)
Westlake R: *See* **Cahn DA**
Williams WA: *See* **George MS** (spring)
Winney G: *See* **Kafantaris V**
Woodard JL: *See* **Cole SA**

Y

Youngstrom EA: *See* **Cole SA**

Z

Zald DH, Kim SW: Anatomy and function of the orbital frontal cortex, I: anatomy, neurocircuitry, and obsessive-compulsive disorder. Spring 125–138; Anatomy and function of the orbital frontal cortex, II: function and relevance to obsessive-compulsive disorder. Summer 249–261

Subject Index

A

Activities of Daily Living
Depression and disability in Parkinson's disease. Cole SA, Woodard JL, Juncos JL, Kogos JL, Youngstrom EA, Watts RL. Winter 20–25
Subcortical hyperintensities on MRI and activities of daily living in geriatric depression. Cahn DA, Malloy PF, Salloway S, Rogg J, Gillard E, Kohn R, Tung G, Richardson ED, Westlake R. Fall 404–411
Aggressiveness and Combativeness
Assessment of children with the Overt Aggression Scale. Kafantaris V, Lee DO, Magee H, Winney G, Samuel R, Pollack S, Campbell M. Spring 186–193
Carbamazepine for combativeness in acute traumatic brain injury (clinical and research report). Chatham-Showalter PE. Winter 96–99
Sertraline in the treatment of severe aggressiveness in Huntington's disease (clinical and research report). Ranen NG, Lipsey JR, Treisman G, Ross CA. Summer 338–340
Aging; *see* **Geriatric Neuropsychiatry**
Alzheimer's Disease; *see* **Dementia**
American Neuropsychiatric Association (ANPA)
ANPA news. Spring 239–240
Animal Studies
Chemical and anatomical plasticity of brain (classic article; introduction by Neylan TC). Bennett EL, Diamond MC, Krech D, Rosenzweig MR. Fall 458–470
Anticoagulant Drugs
Anticoagulant therapy for Alzheimer's disease (letter). Walsh AC. Summer 361 (Reply. Filley CM, Chapman MM, Dubovsky SL. Summer 361–362)
Antipsychotic Drugs
"Abnormal" EEG effects of clozapine (letter). Fink M. Winter 114–115 (Reply. Risby ED, Epstein CM. Winter 115–116)
Clinical utility of clozapine in 16 patients with neurological disease (clinical and research report). Duffy JD, Kant R. Winter 92–96
Clozapine as a treatment for psychosis in Parkinson's disease: a review. Musser WS, Akil M. Winter 1–9
Clozapine for the treatment of psychosis in Parkinson's disease: chart re-

view of 49 patients. Wagner ML, Defilippi JL, Menza MA, Sage JI. Summer 276–280
Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs (classic article; introduction by Neylan TC). Creese I, Burt DR, Snyder SH. Spring 222–226
Anxiety and Panic
Anxiety and Parkinson's disease. Richard IH, Schiffer RB, Kurlan R. Fall 383–392
A survey study of neuropsychiatric complaints in patients with Graves' disease. Stern RA, Robinson B, Thorner AR, Arruda JE, Prohaska ML, Prange AR Jr. Spring 181–185
Apathy
Apathy and loss of insight in Alzheimer's disease: a SPECT imaging study. Ott BR, Noto RB, Fogel BS. Winter 41–46
Asylums
Neuropsychiatry and behavioral neurology: past, present, and future (neuropsychiatric practice and opinion). Benson DF. Summer 351–357
Attention
Event-related potentials as indices of subclinical neurological differences in HIV patients during rapid decision making. Linnville SE, Elliott FS, Larson GE. Spring 293–304
Preliminary evidence of an association between sensorimotor gating and distractibility in psychosis. Karper LP, Freeman GK, Grillon C, Morgan CA III, Charney DS, Krystal JH. Winter 60–66

B

Behavioral Neurology
Neuropsychiatry and behavioral neurology: past, present, and future (neuropsychiatric practice and opinion). Benson DF. Summer 351–357
Bipolar Disorder; *see also* **Depression**; **Mania**
Multiple sclerosis and bipolar disorder: a case report with autopsy findings (clinical and research report). Casanova MF, Kruesi M, Mannheim G. Spring 206–208
Nerve conduction velocity and H-reflex recovery in bipolar illness. El-Mallakh RS, Pant B, Looney SW. Fall 412–416
Poststroke bipolar affective disorder: clinical subtypes, concurrent movement disorders, and anatomical correlates. Berthier ML, Kulisevsky J, Gironell A, Fernández-Benitez JA. Spring 160–167
Books Reviewed
Bischof H, *Pyramidal Neural Networks*. Reviewed by Forrest DV. Fall 472–473
Cameron OG (ed), *Adrenergic Dysfunction and Psychobiology*. Reviewed by McInnes A. Winter 112
Den Boer JA, Westenberg HGM, van Praag HM (eds), *Clinical and Neurobiological Advances in Psychiatry, Vol. 1: Advances in the Neurobiology of Schizophrenia*. Reviewed by Opler LA. Spring 229–230
Ellison JM, Weinstein CS, Hodel-Malinofsky T (eds), *The Psychotherapist's Guide to Neuropsychiatry: Diagnostic and Treatment Issues*. Reviewed by Forrest DV. Spring 227–228
Heilman KM, Valenstein E (eds), *Clinical Neuropsychology*. Reviewed by Watt DF. Summer 359–360
Hollander E, Stein DJ (eds), *Impulsivity and Aggression*. Reviewed by Volavka J. Winter 110–111
Jasper HH, Riggio S, Goldman-Rakic PS (eds), *Epilepsy and the Functional Anatomy of the Frontal Lobe*. Reviewed by Walczak T. Fall 471–472
Lawlor B (ed), *Behavioral Complications in Alzheimer's Disease*. Reviewed by Kunik M. Fall 472
Leonard BE, Miller K (eds), *Stress, the Immune System, and Psychiatry*. Reviewed by Schleifer SJ. Spring 228–229
Roland P, *Brain Activation*. Reviewed by Salloway S. Winter 111–112
Volavka J, *Neurobiology of Violence*. Reviewed by Eichelman BS. Summer 358
Brain; *see also under specific structures*
Anatomy and function of the orbital frontal cortex, II: function and relevance to obsessive-compulsive disorder. Zald DH, Kim SW. Summer 249–261
Poststroke bipolar affective disorder: clinical subtypes, concurrent movement disorders, and anatomical correlates. Berthier ML, Kulisevsky J, Gironell A, Fernández-Benitez JA. Spring 160–167
Chemical and anatomical plasticity of brain (classic article; introduction by Neylan TC). Bennett EL, Diamond MC, Krech D, Rosenzweig MR. Fall 458–470
Anatomy and function of the orbital frontal cortex, I: anatomy, neurocircuitry, and obsessive-compulsive disorder. Zald DH, Kim SW. Spring 125–138
Brain Imaging Studies; *see under specific types*

C

CADASIL
Clinical-pathological case conference: depression, behavior change, and subcortical dementia in a 57-year-old woman (neuropsychiatric practice and opinion). Salloway S. Spring 215–221
Carbamazepine
Carbamazepine for combativeness in acute traumatic brain injury (clinical and research report). Chatham-Showalter PE. Winter 96–99
Children
Assessment of children with the Overt Aggression Scale. Kafantaris V, Lee DO, Magee H, Winney G, Samuel R, Pollack S, Campbell M. Spring 186–193
Classic Articles
Chemical and anatomical plasticity of brain (introduction by Neylan TC). Bennett EL, Diamond MC, Krech D, Rosenzweig MR. Fall 458–470
Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs (introduction by Neylan TC). Creese I, Burt DR, Snyder SH. Spring 222–226
Clomipramine
A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. Petracca G, Tesón A, Chemerinski E, Leiguarda R, Starkstein SE. Summer 270–275
Cocaine; *see* **Substance Abuse**
Compulsive Personality Disorder (DSM-III)
Impulsivity and serotonergic function in compulsive personality disorder. Stein DJ, Trestman RL, Mitropoulou V, Coccaro EF, Hollander E, Siever LJ. Fall 393–398
Computed Tomography Studies
Poststroke bipolar affective disorder: clinical subtypes, concurrent movement disorders, and anatomical correlates. Berthier ML, Kulisevsky J, Gironell A, Fernández-Benitez JA. Spring 160–167
Creatine Phosphate
Effect of photic stimulation on energy metabolism in the human brain measured by ^{31}P-MR spectroscopy. Kato T, Murashita J, Shioiri T, Hamakawa H, Inubushi T. Fall 417–422
Cultural Issues
Cross-cultural perspective in treatment of brain injury (letter). Vompe L. Winter 116
Cyclophosphamide
Conditioning of cyclophosphamide-in-

duced leukopenia in humans. Giang DW, Goodman AD, Schiffer RB, Mattson DH, Petrie M, Cohen N, Ader R. Spring 194–201

D

Delusional Disorder
A clinical and neuropsychological comparison of delusional disorder and schizophrenia. Evans JD, Paulsen JS, Harris MJ, Heaton RK, Jeste DV. Summer 281–286

Dementia
Anticoagulant therapy for Alzheimer's disease (letter). Walsh AC. Summer 361 (Reply. Filley CM, Chapman MM, Dubovsky SL. Summer 361–362)
Apathy and loss of insight in Alzheimer's disease: a SPECT imaging study. Ott BR, Noto RB, Fogel BS. Winter 41–46
Apo-E genotype and verbal deficits in Alzheimer's disease (clinical and research report). Rasmusson DX, Dal Forno G, Brandt J, Warren AC, Troncoso J, Lyketsos C. Summer 335–337
Clinical-pathological case conference: depression, behavior change, and subcortical dementia in a 57-year-old woman (neuropsychiatric practice and opinion). Salloway S. Spring 215–221
A controlled study into the effects of psychoeducation for patients with cognitive disturbances. Commissaris K, Verhey FRJ, Jolles J. Fall 429–435
A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. Petracca G, Tesón A, Chemerinski E, Leiguarda R, Starkstein SE. Summer 270–275
Ethical concerns in the use of palliative drug treatment for Alzheimer's disease (clinical and research report). Filley CM, Chapman MM, Dubovsky SL. Spring 202–205
Frontotemporal dementia: a clinicopathological review of four postmortem studies. Hooten WM, Lyketsos CG. Winter 10–19
Gender differences in cortical glucose metabolism in Alzheimer's disease (clinical and research report). Siegel BV Jr, Shihabuddin L, Buchsbaum MS, Starr A, Haier RJ, Valladares Neto DC. Spring 211–214
Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Lyketsos CG, Corazzini K, Steele CD, Kraus MF. Winter 67–73

Depression
Characterization of major depression symptoms in multiple sclerosis patients. Scott TF, Allen D, Price TRP, McConnell H, Lang D. Summer 318–323
Clinical-pathological case conference: depression, behavior change, and subcortical dementia in a 57-year-old woman (neuropsychiatric practice and opinion). Salloway S. Spring 215–221
Depression associated with stroke (neuropsychiatric practice and opinion). House A. Fall 453–457
Depression and disability in Parkinson's disease. Cole SA, Woodard JL, Juncos JL, Kogos JL, Youngstrom EA, Watts RL. Winter 20–25
A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. Petracca G, Tesón A, Chemerinski E, Leiguarda R, Starkstein SE. Summer 270–275
Lesion characteristics and depressed mood in the stroke data bank study. Morris PLP, Robinson RG, de Carvalho ML, Albert P, Wells JC, Samuels JF, Eden-Fetzer D, Price TR. Spring 153–159
Lesion location and poststroke depression. Morris PLP, Robinson RG, Raphael B, Hopwood MJ. Fall 399–403
The relationship of epileptic auras and psychological attributes. Mendez MF, Engebrit B, Doss R, Grau R. Summer 287–292
Subcortical hyperintensities on MRI and activities of daily living in geriatric depression. Cahn DA, Malloy PF, Salloway S, Rogg J, Gillard E, Kohn R, Tung G, Richardson ED, Westlake R. Fall 404–411
Suicidal plans following spinal cord injury: a six-month study (clinical and research report). Kishi Y, Robinson RG. Fall 442–445
Sustained antidepressant effect of PEA replacement. Sabelli H, Fink P, Fawcett J, Tom C. Spring 168–171

Diagnosis
A clinical and neuropsychological comparison of delusional disorder and schizophrenia. Evans JD, Paulsen JS, Harris MJ, Heaton RK, Jeste DV. Summer 281–286
Clinical-pathological case conference: depression, behavior change, and subcortical dementia in a 57-year-old woman (neuropsychiatric practice and opinion). Salloway S. Spring 215–221
DSM-IV postconcussional disorder: recommendations (letter). Malec JF. Winter 113–114
A survey study of neuropsychiatric complaints in patients with Graves' disease. Stern RA, Robinson B, Thorner AR, Arruda JE, Prohaska ML, Prange AR Jr. Spring 181–185
Unsuspected multiple sclerosis in patients with psychiatric disorders: a magnetic resonance imaging study. Lyoo IK, Seol HY, Byun HS, Renshaw PF. Winter 54–59

Disability; *see* **Activities of Daily Living**

Dopamine
Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs (classic article; introduction by Neylan TC). Creese I, Burt DR, Snyder SH. Spring 222–226

DSM-IV
Chronic substance-induced psychotic disorders: state of the literature. Boutros NN, Bowers MB Jr. Summer 262–269
DSM-IV postconcussional disorder: recommendations (letter). Malec JF. Winter 113–114

E

Elderly; *see* **Geriatric Neuropsychiatry**

Electroconvulsive Therapy (ECT)
ECT in genetically confirmed Huntington's disease (clinical and research report). Lewis CF, DeQuardo JR, Tandon R. Spring 209–210

Electroencephalography (EEG)
"Abnormal" EEG effects of clozapine (letter). Fink M. Winter 114–115 (Reply. Risby ED, Epstein CM. Winter 115–116)
Dimensional complexity of EEG waveforms in neuroleptic-free schizophrenic patients and normal control subjects. Hoffman RE, Buchsbaum MS, Jensen RV, Guich SM, Tsai K, Nuechterlein KH. Fall 436–441
Quantified electroencephalographic correlates of relative frontal or parietal hypoperfusion in dementia. Pozzi D, Vázquez S, Petracchi M, Dancygier G, García H, Starkstein S. Winter 26–32

Epilepsy
Neuropsychiatric side effects related to treatment with felbamate (clinical and research report). McConnell H, Snyder PJ, Duffy JD, Weilburg J, Valeriano J, Brillman J, Cress K, Cavalier J. Summer 341–346
The relationship of epileptic auras and psychological attributes. Mendez MF,

Engebrit B, Doss R, Grau R. Summer 287–292

Ethical Issues

Anticoagulant therapy for Alzheimer's disease (letter). Walsh AC. Summer 361 (Reply. Filley CM, Chapman MM, Dubovsky SL. Summer 361–362)

Ethical concerns in the use of palliative drug treatment for Alzheimer's disease (clinical and research report). Filley CM, Chapman MM, Dubovsky SL. Spring 202–205

Event-Related Potentials and Evoked Potentials

Consistency of repeated event-related potentials in clinically stable HIV-1–infected drug users. Schroeder MM, Handelsman L, Torres L, Jacobson J, Ritter W. Summer 305–310

Differential associations of P300 amplitude and latency with cognitive and psychiatric function in solvent-exposed adults (clinical and research report). Morrow LA, Steinhauer SR, Condray R. Fall 446–449

Event-related potentials as indices of subclinical neurological differences in HIV patients during rapid decision making. Linnville SE, Elliott FS, Larson GE. Spring 293–304

Event-related potentials in schizotypal personality disorder. Trestman RL, Horvath T, Kalus O, Peterson AE, Coccaro E, Mitropoulou V, Apter S, Davidson M, Siever LJ. Winter 33–40

Eyes; *see* **Vision and Eye Movement**

F

Facial Recognition

Neural substrates of facial recognition. Andreasen NC, O'Leary DS, Arndt S, Cizadlo T, Hurtig R, Rezai K, Watkins L, Boles Ponto L, Hichwa RD. Spring 139–146

Felbamate

Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs (classic article; introduction by Neylan TC). Creese I, Burt DR, Snyder SH. Spring 222–226

Neuropsychiatric side effects related to treatment with felbamate (clinical and research report). McConnell H, Snyder PJ, Duffy JD, Weilburg J, Valeriano J, Brillman J, Cress K, Cavalier J. Summer 341–346

Frontotemporal Dementia

Frontotemporal dementia: a clinicopathological review of four postmortem studies. Hooten WM, Lyketsos CG. Winter 10–19

Functioning; *see* **Activities of Daily Living**

G

Gender Differences

Gender differences in cortical glucose metabolism in Alzheimer's disease (clinical and research report). Siegel BV Jr, Shihabuddin L, Buchsbaum MS, Starr A, Haier RJ, Valladares Neto DC. Spring 211–214

Genes

Apo-E genotype and verbal deficits in Alzheimer's disease (clinical and research report). Rasmusson DX, Dal Forno G, Brandt J, Warren AC, Troncoso J, Lyketsos C. Summer 335–337

Clinical-pathological case conference: depression, behavior change, and subcortical dementia in a 57-year-old woman (neuropsychiatric practice and opinion). Salloway S. Spring 215–221

Geriatric Neuropsychiatry; *see also* **Dementia**

An optical intervention for visual hallucinations associated with visual impairment and dementia in elderly patients (clinical and research report). Pankow L, Pliskin N, Luchins D. Winter 88–92

Subcortical hyperintensities on MRI and activities of daily living in geriatric depression. Cahn DA, Malloy PF, Salloway S, Rogg J, Gillard E, Kohn R, Tung G, Richardson ED, Westlake R. Fall 404–411

Graves' Disease

A survey study of neuropsychiatric complaints in patients with Graves' disease. Stern RA, Robinson B, Thorner AR, Arruda JE, Prohaska ML, Prange AR Jr. Spring 181–185

H

Hallucinations

Auditory hallucinations and agenesis of the left internal carotid artery (letter). Cassar J, Vieweg WVR. Spring 231

An optical intervention for visual hallucinations associated with visual impairment and dementia in elderly patients (clinical and research report). Pankow L, Pliskin N, Luchins D. Winter 88–92

Head Injury

Carbamazepine for combativeness in acute traumatic brain injury (clinical and research report). Chatham-Showalter PE. Winter 96–99

Cross-cultural perspective in treatment of brain injury (letter). Vompe L. Winter 116

DSM-IV postconcussional disorder: recommendations (letter). Malec JF. Winter 113–114

Local cerebral glucose metabolism in patients with long-term behavioral and cognitive deficits following mild traumatic brain injury. Gross H, Kling A, Henry G, Herndon C, Lavretsky H. Summer 324–334

Homovanillic Acid (HVA)

Plasma HVA and MHPG in psychiatric patients with renal failure and levodopa-treated Parkinson's disease (clinical and research report). Bowers MB Jr. Fall 450–452

Human Immunodeficiency Virus (HIV)

Consistency of repeated event-related potentials in clinically stable HIV-1–infected drug users. Schroeder MM, Handelsman L, Torres L, Jacobson J, Ritter W. Summer 305–310

Event-related potentials as indices of subclinical neurological differences in HIV patients during rapid decision making. Linnville SE, Elliott FS, Larson GE. Spring 293–304

Increased prevalence of septal cavitation in a nonschizophrenic sample: an MRI study of HIV-infected individuals. Lalonde FM, Martin A, Myslobodsky MS. Winter 47–53

Neuropsychological effects of Interferon Alfa-n3 treatment in human immunodeficiency virus-1–infected individuals. Mapou RL, Law WA, Wagner K, Malone JL, Skillman DR. Winter 74–81

Huntington's Disease

ECT in genetically confirmed Huntington's disease (clinical and research report). Lewis CF, DeQuardo JR, Tandon R. Spring 209–210

Sertraline in the treatment of severe aggressiveness in Huntington's disease (clinical and research report). Ranen NG, Lipsey JR, Treisman G, Ross CA. Summer 338–340

I

Impulsivity

Impulsivity and serotonergic function in compulsive personality disorder. Stein DJ, Trestman RL, Mitropoulou V, Coccaro EF, Hollander E, Siever LJ. Fall 393–398

Information Processing

Event-related potentials as indices of subclinical neurological differences in HIV patients during rapid decision making. Linnville SE, Elliott FS, Larson GE. Spring 293–304

Interferon Alfa-n3
Neuropsychological effects of Interferon Alfa-n3 treatment in human immunodeficiency virus-1–infected individuals. Mapou RL, Law WA, Wagner K, Malone JL, Skillman DR. Winter 74–81

L

Lateralization
Projective testing and lateralization (letter). Watt DF. Spring 232–233 (Reply. Podell K. Spring 233–234)
Lesion Characteristics
Lesion characteristics and depressed mood in the stroke data bank study. Morris PLP, Robinson RG, de Carvalho ML, Albert P, Wells JC, Samuels JF, Eden-Fetzer D, Price TR. Spring 153–159
Lesion location and poststroke depression. Morris PLP, Robinson RG, Raphael B, Hopwood MJ. Fall 399–403
Leukopenia
Conditioning of cyclophosphamide-induced leukopenia in humans. Giang DW, Goodman AD, Schiffer RB, Mattson DH, Petrie M, Cohen N, Ader R. Spring 194–201
Levodopa
Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients. Wagner ML, Defilippi JL, Menza MA, Sage JI. Summer 276–280
Plasma HVA and MHPG in psychiatric patients with renal failure and levodopa-treated Parkinson's disease (clinical and research report). Bowers MB Jr. Fall 450–452

M

Magnetic Resonance Imaging (MRI) Studies
Increased prevalence of septal cavitation in a nonschizophrenic sample: an MRI study of HIV-infected individuals. Lalonde FM, Martin A, Myslobodsky MS. Winter 47–53
Poststroke bipolar affective disorder: clinical subtypes, concurrent movement disorders, and anatomical correlates. Berthier ML, Kulisevsky J, Gironell A, Fernández-Benitez JA. Spring 160–167
Subcortical hyperintensities on MRI and activities of daily living in geriatric depression. Cahn DA, Malloy PF, Salloway S, Rogg J, Gillard E, Kohn R, Tung G, Richardson ED, Westlake R. Fall 404–411
Unsuspected multiple sclerosis in patients with psychiatric disorders: a magnetic resonance imaging study. Lyoo IK, Seol HY, Byun HS, Renshaw PF. Winter 54–59
Magnetic Resonance Spectroscopy (MRS)
Effect of photic stimulation on energy metabolism in the human brain measured by ^{31}P-MR spectroscopy. Kato T, Murashita J, Shioiri T, Hamakawa H, Inubushi T. Fall 417–422
Mania; *see also* **Bipolar Disorder**
Multiple sclerosis and bipolar disorder: a case report with autopsy findings (clinical and research report). Casanova MF, Kruesi M, Mannheim G. Spring 206–208
Memory
Recall and recognition memory in obsessive-compulsive disorder (clinical and research report). Savage CR, Keuthen NJ, Jenike MA, Brown HD, Baer L, Kendrick AD, Miguel EC, Rauch SL, Albert MS. Winter 99–103
3-Methoxy-4-Hydroxyphenylglycol (MHPG)
Plasma HVA and MHPG in psychiatric patients with renal failure and levodopa-treated Parkinson's disease (clinical and research report). Bowers MB Jr. Fall 450–452
Movement Disorders
Poststroke bipolar affective disorder: clinical subtypes, concurrent movement disorders, and anatomical correlates. Berthier ML, Kulisevsky J, Gironell A, Fernández-Benitez JA. Spring 160–167
Multiple Sclerosis
Characterization of major depression symptoms in multiple sclerosis patients. Scott TF, Allen D, Price TRP, McConnell H, Lang D. Summer 318–323
Multiple sclerosis and bipolar disorder: a case report with autopsy findings (clinical and research report). Casanova MF, Kruesi M, Mannheim G. Spring 206–208
Unsuspected multiple sclerosis in patients with psychiatric disorders: a magnetic resonance imaging study. Lyoo IK, Seol HY, Byun HS, Renshaw PF. Winter 54–59

N

Neural Network Models
Projective testing and lateralization (letter). Watt DF. Spring 232–233 (Reply. Podell K. Spring 233–234)
Neuropsychiatric Practice and Opinion
Clinical-pathological case conference: depression, behavior change, and subcortical dementia in a 57-year-old woman. Salloway S. Spring 215–221
Depression associated with stroke. House A. Fall 453–457
Neuropsychiatry and behavioral neurology: past, present, and future. Benson DF. Summer 351–357
Neuropsychiatry and society. Cummings JL. Winter 104–109
Neuropsychiatry as Field
Neuropsychiatry and behavioral neurology: past, present, and future (neuropsychiatric practice and opinion). Benson DF. Summer 351–357
Neuropsychiatry and society (neuropsychiatric practice and opinion). Cummings JL. Winter 104–109
On neuropsychiatry and society (letter). Mender D. Summer 362–363
Neuropsychology
Assessment of children with the Overt Aggression Scale. Kafantaris V, Lee DO, Magee H, Winney G, Samuel R, Pollack S, Campbell M. Spring 186–193
A clinical and neuropsychological comparison of delusional disorder and schizophrenia. Evans JD, Paulsen JS, Harris MJ, Heaton RK, Jeste DV. Summer 281–286
Chemical and anatomical plasticity of brain (classic article; introduction by Neylan TC). Bennett EL, Diamond MC, Krech D, Rosenzweig MR. Fall 458–470
Assessing the neuropsychological profile of stable schizophrenic outpatients. Cutler NR, Veroff AE, Frackiewicz EJ, Welke TL, Kurtz NM, Sramek JJ. Fall 423–428
Cross-cultural perspective in treatment of brain injury (letter). Vompe L. Winter 116
The effect of a split in WAIS-R VIQ and PIQ scores on patients with cognitive impairment and psychiatric illness (clinical and research report). Hackerman F, Buccino DL, Gallucci G, Schmidt CW Jr. Winter 85–87
Neuropsychological effects of Interferon Alfa-n3 treatment in human immunodeficiency virus-1–infected individuals. Mapou RL, Law WA, Wagner K, Malone JL, Skillman DR. Winter 74–81
Projective testing and lateralization (letter). Watt DF. Spring 232–233 (Reply. Podell K. Spring 233–234)
Specificity of neuropsychological impairment in obsessive-compulsive disorder: a comparison with social phobic and normal control subjects (clinical and research report). Cohen LJ, Hollander E, DeCaria CM, Stein DJ, Simeon D, Liebowitz MR, Aronowitz

BR. Winter 82–84
Nimodipine
Ethical concerns in the use of palliative drug treatment for Alzheimer's disease (clinical and research report). Filley CM, Chapman MM, Dubovsky SL. Spring 202–205

O

Obsessive-Compulsive Disorder
Anatomy and function of the orbital frontal cortex, I: anatomy, neurocircuitry, and obsessive-compulsive disorder. Zald DH, Kim SW. Spring 125–138
Anatomy and function of the orbital frontal cortex, II: function and relevance to obsessive-compulsive disorder. Zald DH, Kim SW. Summer 249–261
Recall and recognition memory in obsessive-compulsive disorder (clinical and research report). Savage CR, Keuthen NJ, Jenike MA, Brown HD, Baer L, Kendrick AD, Miguel EC, Rauch SL, Albert MS. Winter 99–103
Specificity of neuropsychological impairment in obsessive-compulsive disorder: a comparison with social phobic and normal control subjects (clinical and research report). Cohen LJ, Hollander E, DeCaria CM, Stein DJ, Simeon D, Liebowitz MR, Aronowitz BR. Winter 82–84
Orbital Frontal Cortex
Anatomy and function of the orbital frontal cortex, I: anatomy, neurocircuitry, and obsessive-compulsive disorder. Zald DH, Kim SW. Spring 125–138
Anatomy and function of the orbital frontal cortex, II: function and relevance to obsessive-compulsive disorder. Zald DH, Kim SW. Summer 249–261

P

Paranoia
A measure of pupillary oscillation as a marker of cocaine-induced paranoia (clinical and research report). Rosse RB, Johri SK, Hess AL, Kendrick K, Alim TN, Deutsch SI. Summer 347–350
Parkinson's Disease
Anxiety and Parkinson's disease. Richard IH, Schiffer RB, Kurlan R. Fall 383–392
Clozapine as a treatment for psychosis in Parkinson's disease: a review. Musser WS, Akil M. Winter 1–9
Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients. Wagner ML, Defilippi JL, Menza MA, Sage JI. Summer 276–280
Depression and disability in Parkinson's disease. Cole SA, Woodard JL, Juncos JL, Kogos JL, Youngstrom EA, Watts RL. Winter 20–25
Plasma HVA and MHPG in psychiatric patients with renal failure and levodopa-treated Parkinson's disease (clinical and research report). Bowers MB Jr. Fall 450–452
PET Studies
Gender differences in cortical glucose metabolism in Alzheimer's disease (clinical and research report). Siegel BV Jr, Shihabuddin L, Buchsbaum MS, Starr A, Haier RJ, Valladares Neto DC. Spring 211–214
Local cerebral glucose metabolism in patients with long-term behavioral and cognitive deficits following mild traumatic brain injury. Gross H, Kling A, Henry G, Herndon C, Lavretsky H. Summer 324–334
Neural substrates of facial recognition. Andreasen NC, O'Leary DS, Arndt S, Cizadlo T, Hurtig R, Rezai K, Watkins L, Boles Ponto L, Hichwa RD. Spring 139–146
Phenylethylamine (PEA)
Sustained antidepressant effect of PEA replacement. Sabelli H, Fink P, Fawcett J, Tom C. Spring 168–171
Postconcussional Disorder; *see also* **Head Injury**
DSM-IV postconcussional disorder: recommendations (letter). Malec JF. Winter 113–114
Prefrontal Cortex
Changes in mood and hormone levels after rapid-rate transcranial magnetic stimulation (rTMS) of the prefrontal cortex. George MS, Wassermann EM, Williams WA, Steppel J, Pascual-Leone A, Basser P, Hallett M, Post RM. Spring 172–180
Psychoeducation
A controlled study into the effects of psychoeducation for patients with cognitive disturbances. Commissaris K, Verhey FRJ, Jolles J. Fall 429–435
Psychosis; *see also* **Schizophrenia**
Chronic substance-induced psychotic disorders: state of the literature. Boutros NN, Bowers MB Jr. Summer 262–269
Clozapine as a treatment for psychosis in Parkinson's disease: a review. Musser WS, Akil M. Winter 1–9
Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients. Wagner ML, Defilippi JL, Menza MA, Sage JI. Summer 276–280
Preliminary evidence of an association between sensorimotor gating and distractibility in psychosis. Karper LP, Freeman GK, Grillon C, Morgan CA III, Charney DS, Krystal JH. Winter 60–66

S

Schizophrenia
Assessing the neuropsychological profile of stable schizophrenic outpatients. Cutler NR, Veroff AE, Frackiewicz EJ, Welke TL, Kurtz NM, Sramek JJ. Fall 423–428
A clinical and neuropsychological comparison of delusional disorder and schizophrenia. Evans JD, Paulsen JS, Harris MJ, Heaton RK, Jeste DV. Summer 281–286
Dimensional complexity of EEG waveforms in neuroleptic-free schizophrenic patients and normal control subjects. Hoffman RE, Buchsbaum MS, Jensen RV, Guich SM, Tsai K, Nuechterlein KH. Fall 436–441
Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs (classic article; introduction by Neylan TC). Creese I, Burt DR, Snyder SH. Spring 222–226
Increased prevalence of septal cavitation in a nonschizophrenic sample: an MRI study of HIV-infected individuals. Lalonde FM, Martin A, Myslobodsky MS. Winter 47–53
Pattern of brain morphology in patients with schizophrenia and large cavum septi pellucidi. Nopoulos P, Swayze V, Andreasen NC. Spring 147–152
Schizotypal Personality Disorder
Event-related potentials in schizotypal personality disorder. Trestman RL, Horvath T, Kalus O, Peterson AE, Coccaro E, Mitropoulou V, Apter S, Davidson M, Siever LJ. Winter 33–40
Sensorimotor Gating
Preliminary evidence of an association between sensorimotor gating and distractibility in psychosis. Karper LP, Freeman GK, Grillon C, Morgan CA III, Charney DS, Krystal JH. Winter 60–66
Septum Pellucidum
Abnormal septum pellucidum morphology in Tourette's syndrome (letter). Sieg KG. Fall 474
Increased prevalence of septal cavitation in a nonschizophrenic sample: an MRI study of HIV-infected individu-

als. Lalonde FM, Martin A, Myslobodsky MS. Winter 47–53

Serotonin

Impulsivity and serotonergic function in compulsive personality disorder. Stein DJ, Trestman RL, Mitropoulou V, Coccaro EF, Hollander E, Siever LJ. Fall 393–398

Sertraline

Sertraline in the treatment of severe aggressiveness in Huntington's disease (clinical and research report). Ranen NG, Lipsey JR, Treisman G, Ross CA. Summer 338–340

Social Behavior

Non-obscene complex socially inappropriate behavior in Tourette's syndrome. Kurlan R, Daragjati C, Como PG, McDermott MP, Trinidad KS, Roddy S, Brower CA, Robertson MM. Summer 311–317

Specificity of neuropsychological impairment in obsessive-compulsive disorder: a comparison with social phobic and normal control subjects (clinical and research report). Cohen LJ, Hollander E, DeCaria CM, Stein DJ, Simeon D, Liebowitz MR, Aronowitz BR. Winter 82–84

Solvents

Differential associations of P300 amplitude and latency with cognitive and psychiatric function in solvent-exposed adults (clinical and research report). Morrow LA, Steinhauer SR, Condray R. Fall 446–449

SPECT Studies

Apathy and loss of insight in Alzheimer's disease: a SPECT imaging study. Ott BR, Noto RB, Fogel BS. Winter 41–46

Spinal Cord Injury

Suicidal plans following spinal cord injury: a six-month study (clinical and research report). Kishi Y, Robinson RG. Fall 442–445

Stroke

Depression associated with stroke (neuropsychiatric practice and opinion). House A. Fall 453–457

Lesion characteristics and depressed mood in the stroke data bank study. Morris PLP, Robinson RG, de Carvalho ML, Albert P, Wells JC, Samuels JF, Eden-Fetzer D, Price TR. Spring 153–159

Lesion location and poststroke depression. Morris PLP, Robinson RG, Raphael B, Hopwood MJ. Fall 399–403

Poststroke bipolar affective disorder: clinical subtypes, concurrent movement disorders, and anatomical correlates. Berthier ML, Kulisevsky J, Gironell A, Fernández-Benitez JA. Spring 160–167

Subcortical Hyperintensities

Subcortical hyperintensities on MRI and activities of daily living in geriatric depression. Cahn DA, Malloy PF, Salloway S, Rogg J, Gillard E, Kohn R, Tung G, Richardson ED, Westlake R. Fall 404–411

Substance Abuse

Chronic substance-induced psychotic disorders: state of the literature. Boutros NN, Bowers MB Jr. Summer 262–269

Consistency of repeated event-related potentials in clinically stable HIV-1–infected drug users. Schroeder MM, Handelsman L, Torres L, Jacobson J, Ritter W. Summer 305–310

A measure of pupillary oscillation as a marker of cocaine-induced paranoia (clinical and research report). Rosse RB, Johri SK, Hess AL, Kendrick K, Alim TN, Deutsch SI. Summer 347–350

Suicidality

Suicidal plans following spinal cord injury: a six-month study (clinical and research report). Kishi Y, Robinson RG. Fall 442–445

T

Tacrine

Ethical concerns in the use of palliative drug treatment for Alzheimer's disease (clinical and research report). Filley CM, Chapman MM, Dubovsky SL. Spring 202–205

Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Lyketsos CG, Corazzini K, Steele CD, Kraus MF. Winter 67–73

Tourette's Syndrome

Abnormal septum pellucidum morphology in Tourette's syndrome (letter). Sieg KG. Fall 474

Non-obscene complex socially inappropriate behavior in Tourette's syndrome. Kurlan R, Daragjati C, Como PG, McDermott MP, Trinidad KS, Roddy S, Brower CA, Robertson MM. Summer 311–317

Transcranial Magnetic Stimulation

Changes in mood and hormone levels after rapid-rate transcranial magnetic stimulation (rTMS) of the prefrontal cortex. George MS, Wassermann EM, Williams WA, Steppel J, Pascual-Leone A, Basser P, Hallett M, Post RM. Spring 172–180

Transcranial magnetic stimulation: a neuropsychiatric tool for the 21st century. George MS, Wassermann EM, Post RM. Fall 373–382

Treatment Guidelines

Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Lyketsos CG, Corazzini K, Steele CD, Kraus MF. Winter 67–73

V

Valproic Acid

Neuropsychiatric side effects related to treatment with felbamate (clinical and research report). McConnell H, Snyder PJ, Duffy JD, Weilburg J, Valeriano J, Brillman J, Cress K, Cavalier J. Summer 341–346

Verbal Deficits

Apo-E genotype and verbal deficits in Alzheimer's disease (clinical and research report). Rasmusson DX, Dal Forno G, Brandt J, Warren AC, Troncoso J, Lyketsos C. Summer 335–337

Vision and Eye Movement

Effect of photic stimulation on energy metabolism in the human brain measured by ^{31}P-MR spectroscopy. Kato T, Murashita J, Shioiri T, Hamakawa H, Inubushi T. Fall 417–422

A measure of pupillary oscillation as a marker of cocaine-induced paranoia (clinical and research report). Rosse RB, Johri SK, Hess AL, Kendrick K, Alim TN, Deutsch SI. Summer 347–350

An optical intervention for visual hallucinations associated with visual impairment and dementia in elderly patients (clinical and research report). Pankow L, Pliskin N, Luchins D. Winter 88–92